F5682
FH535
≥98% (HPLC)
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C13H10Cl2N2O4S
化学文摘社编号:
分子量:
361.20
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI key
AXNUEXXEQGQWPA-UHFFFAOYSA-N
SMILES string
Cc1cc(ccc1NS(=O)(=O)c2cc(Cl)ccc2Cl)[N+]([O-])=O
InChI
1S/C13H10Cl2N2O4S/c1-8-6-10(17(18)19)3-5-12(8)16-22(20,21)13-7-9(14)2-4-11(13)15/h2-7,16H,1H3
assay
≥98% (HPLC)
form
solid
solubility
DMSO: 20 mg/mL
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
FH535 has the ability to block the development of colon cancer cells. It can change several cancer-associated biological processes. FH535 can also prevent PARylation of Axin2 in osteosarcoma cells.
FH535 is a reversible dual inhibitor of Wnt/β-catenin and PPARγ and PPARδ signaling antagonist; β-catenin/Tcf inhibitor.
FH535 is a reversible dual inhibitor of Wnt/β-catenin and a PPARγ and PPARδ signaling antagonist. FH535 is unique in its ability to inhibit the Wnt/β-catenin pathway. The compound is selectively toxic to some carcinomas expressing the Wnt/β-catenin pathway.
存储类别
11 - Combustible Solids
wgk
WGK 3
Fu-Lai Zhou et al.
Acta pharmacologica Sinica, 40(9), 1245-1255 (2019-05-30)
Chemical genomics has been applied extensively to evaluate small molecules that modulate biological processes in Saccharomyces cerevisiae. Here, we use yeast as a surrogate system for studying compounds that are active against metazoan targets. Large-scale chemical-genetic profiling of thousands of
FH535 Suppresses Osteosarcoma Growth In Vitro and Inhibits Wnt Signaling through Tankyrases
Gustafson C T, et al.
Frontiers in Pharmacology, 8, 285-285 (2017)
Anupama Karnam et al.
Communications biology, 3(1), 96-96 (2020-03-07)
Therapeutic normal IgG intravenous immunoglobulin (IVIG) is a well-established first-line immunotherapy for many autoimmune and inflammatory diseases. Though several mechanisms have been proposed for the anti-inflammatory actions of IVIG, associated signaling pathways are not well studied. As β-catenin, the central
FH535 Inhibits Proliferation and Motility of Colon Cancer Cells by Targeting Wnt beta-catenin Signaling Pathway
Chen Y, et al.
Journal of Cancer, 8(16), 3142-3142 (2017)
Wei Xie et al.
The international journal of biochemistry & cell biology, 103, 45-55 (2018-08-11)
Triple negative breast cancer (TNBC) is one of the most difficult malignancy to treat due to a lack of targeted therapy. Studies have demonstrated that the activation of Wnt/β-catenin signaling was preferentially found in TNBC. Frizzled-7 (Fzd7), one of the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持